GlassScriptPhysician profile
John F Mills
NPI 1790738425
$2,040.63
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $144 · 2021: $643 · 2022: $577 · 2023: $389 · 2024: $31.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.05 | 2021-2024 | |
| Irhythm Technologies, INC. | $93.64 | 2019 | |
| Esperion Therapeutics, INC. | $75.38 | 2021 | |
| Xeris Pharmaceuticals, INC. | $62.11 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.42 | 2022 | |
| Glaxosmithkline, LLC. | $54.96 | 2020-2021 | |
| Amgen INC. | $51.46 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $50.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.16 | 2021 | |
| Medtronic Vascular, INC. | $48.60 | 2019 | |
| Allergan, INC. | $45.83 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $43.65 | 2020-2021 | |
| Almatica Pharma LLC | $39.47 | 2021-2022 | |
| Novo Nordisk INC | $36.54 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.47 | 2021 | |
| Dexcom, INC. | $31.39 | 2023-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $31.39 | 2021 | |
| Astellas Pharma US INC | $31.22 | 2019-2021 | |
| Pfizer INC. | $26.13 | 2019-2023 | |
| Genentech USA, INC. | $18.35 | 2021 | |
| Merck Sharp & Dohme LLC | $17.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.63 | 2022 | |
| Lilly USA, LLC | $15.51 | 2021 | |
| Edwards Lifesciences Corporation | $14.09 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Paratek Pharmaceuticals, INC. | $14.03 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.16 | 2022 | |
| Therapeuticsmd, INC. | $11.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.64 | 2022 | |
| Amarin Pharma, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.